Last reviewed · How we verify

Digital nerve block with bupivacaine

Tehran University of Medical Sciences · FDA-approved active Small molecule

Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia in the digital nerves.

Bupivacaine blocks sodium channels in nerve fibers, preventing the generation and propagation of action potentials to produce local anesthesia in the digital nerves. Used for Digital nerve block for surgical anesthesia of fingers or toes, Pain management during digital procedures.

At a glance

Generic nameDigital nerve block with bupivacaine
SponsorTehran University of Medical Sciences
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. When injected around digital nerves, it prevents depolarization and conduction of pain signals, resulting in sensory and motor blockade of the fingers or toes. The effect is localized to the injection site and is reversible as the drug is metabolized and redistributed.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: